Ultragenyx Pharmaceutical (RARE) Given Coverage Optimism Rating of 0.15

News articles about Ultragenyx Pharmaceutical (NASDAQ:RARE) have been trending somewhat positive this week, according to Accern Sentiment Analysis. Accern identifies negative and positive news coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Ultragenyx Pharmaceutical earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned media headlines about the biopharmaceutical company an impact score of 46.6334596705394 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.

These are some of the media headlines that may have effected Accern’s scoring:

Get Ultragenyx Pharmaceutical alerts:

Burosumab Improves Outcomes in Children with XLH in Phase 2 Trial (raredr.com) RARE Stock Is on the Verge of Breaking Out Toward Higher Prices (profitconfidential.com) Burosumab may benefit children with X-linked hypophosphatemia (medicalxpress.com) A Look Inside the Quant Data For Ultragenyx Pharmaceutical Inc. (NasdaqGS:RARE) (parkcitycaller.com) Ultragenyx Pharmaceutical Inc. (RARE)- Stock in the Trader’s Radar (nasdaqfortune.com)

A number of research firms have recently weighed in on RARE. ValuEngine raised Ultragenyx Pharmaceutical from a “hold” rating to a “buy” rating in a report on Saturday. BidaskClub raised Ultragenyx Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Barclays raised Ultragenyx Pharmaceutical from an “equal weight” rating to an “overweight” rating and lifted their target price for the stock from $62.00 to $74.00 in a report on Friday, May 11th. Goldman Sachs Group began coverage on Ultragenyx Pharmaceutical in a report on Thursday, May 10th. They set a “neutral” rating and a $63.00 target price for the company. Finally, Zacks Investment Research downgraded Ultragenyx Pharmaceutical from a “hold” rating to a “sell” rating in a report on Tuesday, January 30th. One research analyst has rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $70.06.

Shares of NASDAQ RARE opened at $67.31 on Friday. Ultragenyx Pharmaceutical has a 52 week low of $41.67 and a 52 week high of $71.99. The firm has a market capitalization of $3.25 billion, a P/E ratio of -8.97 and a beta of 1.83.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings results on Monday, May 7th. The biopharmaceutical company reported $0.62 EPS for the quarter, topping the Zacks’ consensus estimate of ($0.19) by $0.81. The company had revenue of $10.68 million during the quarter, compared to the consensus estimate of $56.58 million. During the same quarter in the previous year, the business posted ($1.63) EPS. analysts expect that Ultragenyx Pharmaceutical will post -5.51 EPS for the current fiscal year.

In related news, EVP Karah Herdman Parschauer sold 1,465 shares of the firm’s stock in a transaction on Thursday, May 10th. The stock was sold at an average price of $60.00, for a total value of $87,900.00. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. 8.40% of the stock is currently owned by company insiders.

Ultragenyx Pharmaceutical Company Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of various products for the treatment of rare and ultra-rare genetic diseases in the United States. Its biologics product candidate includes Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII.

Insider Buying and Selling by Quarter for Ultragenyx Pharmaceutical (NASDAQ:RARE)

Leave a Reply

Your email address will not be published. Required fields are marked *